Flatiron Health

Flatiron Health is a New York City-based healthtech company that provides specialized technology and software services to improve cancer treatment and advance oncology research by analyzing real-world patient data. The organization currently partners with hundreds of cancer centers and more than 20 global oncology therapeutics developers to successfully bridge the critical gap between daily clinical care and scientific research. Operating as an independent corporate affiliate of the Roche Group following its acquisition in 2018, the enterprise has steadily expanded its international operational presence with new subsidiaries located in Japan, Germany, and the United Kingdom. Under the strategic direction of Chief Executive Officer Nathan Hubbard and Chief Technology Officer Allison Candido, the firm supplies data-driven clinical evidence to researchers, healthcare providers, and regulatory agencies worldwide. Flatiron Health was founded in 2012 by Nat Turner and Zach Weinberg.

# Flatiron Health: High-Level Overview

Flatiron Health is a healthtech company dedicated to improving cancer treatment and advancing research through real-world evidence and point-of-care software solutions.[5] The company serves cancer centers, oncologists, pharmaceutical developers, and researchers by providing integrated technology platforms that bridge the gap between clinical care and research.[3] Flatiron solves a critical infrastructure problem in oncology: cancer centers lack efficient tools to manage patient data, streamline workflows, and contribute to research simultaneously. The company's growth momentum is substantial—it operates across multiple global markets with over 2,500 employees, partners with hundreds of cancer centers and 20+ leading oncology drug developers, and has generated real-world evidence from over 5 million de-identified patient records containing 1.5 billion data points.[6]

Flatiron's business model centers on aggregating and analyzing clinical data at scale to create actionable insights for multiple stakeholders. For care providers, the company reduces administrative burden and improves financial viability. For pharmaceutical companies and regulators, it accelerates drug development by providing robust real-world evidence that supports regulatory submissions and informs treatment strategies.[7]

Origin Story

Flatiron Health was founded in 2012 as a pioneer in real-world evidence for oncology.[4][5] The company emerged from a recognition that cancer care operated in silos—clinical practices generated rich patient data that remained disconnected from research and drug development. In 2018, Roche acquired Flatiron, establishing it as an independent affiliate within the Roche Group.[4] This acquisition validated the company's mission while providing resources to scale its platform globally. The company is headquartered in New York and has expanded to operations in the UK, Germany, and Japan.[4]

Core Differentiators

• Proprietary oncology data at scale: Flatiron Horizon, the company's core platform, integrates the richest labeled oncology dataset in the world with proprietary curation methods and disease-specific machine learning models.[6] This creates a defensible moat—competitors cannot easily replicate years of accumulated, curated clinical data.

• Point-of-care software designed by oncologists: Tools like Flatiron Assist™ and OncoAir™ are engineered to reduce clinician burden rather than add to it, surfacing evidence-based treatment options and clinical trials without disrupting workflows.[1] This user-centric design drives adoption among busy care teams.

• End-to-end lifecycle support for biopharma: Flatiron provides tailored real-world evidence services across the entire drug development lifecycle—from pre-market research to post-launch monitoring—with 350+ custom projects delivered and 50+ regulatory submissions supported.[7]

• Deep regulatory relationships: The company has 5+ years of direct collaboration with the FDA, NICE, and other health technology assessment bodies, positioning it as a trusted partner for evidence generation that regulators recognize and value.[6][7]

• Precision medicine integration: Flatiron's precision medicine suite enables oncologists to understand tumor biology and match patients to clinical trials, bringing advanced treatment matching to the point of care.[1]

Role in the Broader Tech Landscape

Flatiron operates at the intersection of three powerful trends: real-world evidence adoption in drug development, digital transformation in healthcare, and precision oncology. Regulators increasingly accept real-world data to support drug approvals, reducing reliance on traditional clinical trials alone. Simultaneously, cancer centers face mounting pressure to remain financially viable while delivering quality care—creating demand for integrated software solutions. The precision medicine movement requires vast, curated datasets to match patients to targeted therapies, a capability Flatiron uniquely provides at scale.

The company influences the broader ecosystem by standardizing how oncology data is collected, organized, and shared.[8] By connecting community practices and cancer centers on a common infrastructure, Flatiron enables benchmarking and collaborative learning across the industry—transforming cancer care from fragmented silos into a networked, learning system. This positions the company as critical infrastructure for modern oncology.

Quick Take & Future Outlook

Flatiron is well-positioned to deepen its influence as real-world evidence becomes central to drug development and healthcare policy. The company's next frontier likely involves expanding precision medicine capabilities and extending its platform internationally to capture oncology data from additional global markets. As healthcare systems increasingly demand data-driven decision-making and pharmaceutical companies face pressure to demonstrate real-world value, Flatiron's integrated approach—combining care delivery software with research-grade evidence generation—becomes more defensible and valuable.

The company's Roche backing provides both stability and distribution advantages, while its independent operating model preserves the trust of competitors who rely on its data services. In a healthcare landscape moving toward learning health systems, Flatiron has architected itself as the connective tissue that makes that vision possible.